X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CIPLA ALKEM LABORATORIES/
CIPLA
 
P/E (TTM) x - 39.0 - View Chart
P/BV x 6.3 4.0 156.2% View Chart
Dividend Yield % 0.7 0.3 216.2%  

Financials

 ALKEM LABORATORIES   CIPLA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CIPLA
Mar-17
ALKEM LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,589622 255.5%   
Low Rs1,232458 268.8%   
Sales per share (Unadj.) Rs417.5181.9 229.6%  
Earnings per share (Unadj.) Rs56.312.9 437.4%  
Cash flow per share (Unadj.) Rs64.729.3 220.7%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.4 243.2%  
Book value per share (Unadj.) Rs292.9155.7 188.2%  
Shares outstanding (eoy) m119.57804.51 14.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.8%   
Avg P/E ratio x25.142.0 59.7%  
P/CF ratio (eoy) x21.818.4 118.3%  
Price / Book Value ratio x4.83.5 138.8%  
Dividend payout %22.615.5 145.2%   
Avg Mkt Cap Rs m168,653434,516 38.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m9,17126,338 34.8%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m49,915146,302 34.1%  
Other income Rs m1,6452,287 71.9%   
Total revenues Rs m51,561148,589 34.7%   
Gross profit Rs m8,48224,758 34.3%  
Depreciation Rs m1,00613,229 7.6%   
Interest Rs m6711,594 42.1%   
Profit before tax Rs m8,45112,222 69.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,798 89.3%   
Profit after tax Rs m6,73110,354 65.0%  
Gross profit margin %17.016.9 100.4%  
Effective tax rate %19.014.7 129.2%   
Net profit margin %13.57.1 190.5%  
BALANCE SHEET DATA
Current assets Rs m27,06287,370 31.0%   
Current liabilities Rs m15,32433,081 46.3%   
Net working cap to sales %23.537.1 63.4%  
Current ratio x1.82.6 66.9%  
Inventory Days Days6787 76.5%  
Debtors Days Days4162 66.3%  
Net fixed assets Rs m12,610111,567 11.3%   
Share capital Rs m2391,609 14.9%   
"Free" reserves Rs m34,490123,645 27.9%   
Net worth Rs m35,027125,254 28.0%   
Long term debt Rs m1,21236,454 3.3%   
Total assets Rs m54,387209,532 26.0%  
Interest coverage x13.68.7 156.9%   
Debt to equity ratio x00.3 11.9%  
Sales to assets ratio x0.90.7 131.4%   
Return on assets %13.65.7 238.7%  
Return on equity %19.28.3 232.5%  
Return on capital %24.98.5 292.4%  
Exports to sales %12.934.2 37.8%   
Imports to sales %3.18.3 37.0%   
Exports (fob) Rs m6,46150,050 12.9%   
Imports (cif) Rs m1,54012,203 12.6%   
Fx inflow Rs m6,56351,066 12.9%   
Fx outflow Rs m3,01217,678 17.0%   
Net fx Rs m3,55233,388 10.6%   
CASH FLOW
From Operations Rs m7,25923,824 30.5%  
From Investments Rs m1,864-13,127 -14.2%  
From Financial Activity Rs m-9,273-13,239 70.0%  
Net Cashflow Rs m-150-2,478 6.1%  

Share Holding

Indian Promoters % 66.9 16.0 418.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 33.1 12.2 271.3%  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 0.0 26.2 -  
Shareholders   68,381 161,166 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; IT Stocks Lead Gains(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in above the dotted line.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jul 20, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS